# A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

Study · id `cardio:ct-nct04865770` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04865770](<https://clinicaltrials.gov/study/NCT04865770>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04865770

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

## Technical summary

Registry record NCT04865770. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2024-11-21 (actual). Results posted on 2026-01-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 106 participants (enrolled count; ClinicalTrials.gov record NCT04865770, source copy `cardio:ctgov-nct04865770-2026-02-10`, retrieved 2026-11-18)
- Started: 2021-04-28 (actual) (ClinicalTrials.gov record NCT04865770, source copy `cardio:ctgov-nct04865770-2026-02-10`, retrieved 2026-11-18)
- Primary completion: 2024-11-21 (actual) (ClinicalTrials.gov record NCT04865770, source copy `cardio:ctgov-nct04865770-2026-02-10`, retrieved 2026-11-18)
- Completion: 2024-11-21 (actual) (ClinicalTrials.gov record NCT04865770, source copy `cardio:ctgov-nct04865770-2026-02-10`, retrieved 2026-11-18)
- Results first posted: 2026-01-14 (ClinicalTrials.gov record NCT04865770, source copy `cardio:ctgov-nct04865770-2026-02-10`, retrieved 2026-11-18)
- Countries: United States; Canada; Denmark; France; Italy; Poland; South Africa; Spain (ClinicalTrials.gov record NCT04865770, source copy `cardio:ctgov-nct04865770-2026-02-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04865770-2026-02-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
- Acronym: REMODEL
- Condition: Diabetes Mellitus, Type 2
- Condition: Chronic Kidney Disease
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (Semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 201b2b73e04f179101e3414f08ae1ad34a7954da3ecd10a25f4818b7c8da84a6
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
